Boots ECONOMIC

Supply Chain & Sourcing Relationships

A 2008 Jewish Chronicle report quoted a Boots Alliance spokesperson confirming the company “does not currently operate any pharmacy or wholesale business in Israel,” while the same article named Ahava - a Dead Sea cosmetics manufacturer with production historically sited in the West Bank settlement of Mitzpe Shalem - as a supplier that “already supplies Boots” ¹. The article also named CTS Chemical Industries as a supplier the 2008 Boots purchasing delegation (reportedly 10–11 people, with over 25 confirmed supplier meetings) intended to engage with during a planned Tel Aviv seminar on 18 June 2008, organized at the initiation of Gil Erez, trade attaché at the Israeli embassy in London ¹. A 2008 BDS Movement campaign page, citing the same underlying Haaretz and Jewish Chronicle reporting, additionally alleged Boots “may be looking” to expand sourcing from Israeli firms Hlavin Industries, Ein Gedi, NanoDerma, Card Guard, Second Opinion, TransPharma Medical, and Tulip Medical, though this rests on campaign-page characterization of press reports rather than independent corporate confirmation ². The same campaign page states that a Boots customer-services enquiry (undated) reportedly confirmed Boots no longer stocked Ahava products, with no stated reason given, but this is a secondhand account on an advocacy page, not a corporate record, and predates the audit’s currency window by over a decade ². The original Haaretz and Jewish Chronicle 2008 articles cited by the BDS page are now dead links and could not be independently re-verified in this research ^{3, 4}. No public evidence identified confirming whether the Boots–Ahava or Boots–CTS Chemical Industries supplier relationships continued, were modified, or ended after 2008. Who Profits’ profile of settlement-linked agricultural exporter Mehadrin names Tesco, Fruttilal, Amt Ltd., Albert Heijn, and Costco as European/UK marketing channels for Mehadrin’s Jordan Valley and Golan Heights settlement produce, but does not name Boots anywhere in the profile ⁵. A secondary, unfetched search snippet (IsraelDesks) reportedly describes a commercial arrangement in which Boots-branded products are sold in Israel through Super-Pharm, but this claim could not be independently verified against a primary source and is flagged as unresolved ⁶.

Updated research located a dated, independently fetched 5 June 2026 Jewish News (UK) article reporting that Superdrug - a Boots competitor, not Boots itself - removed an Ahava product listing from its online marketplace and blocked future third-party listings of the brand, after being alerted by photographs obtained by the American Friends Service Committee (AFSC), first reported by Sky News, appearing to show chemical containers dated 2025–2026 and material resembling Dead Sea mud at the Mitzpe Shalem site ⁷. The article states that Ahava and its parent company, Fosun International, were added to the UN database of companies linked to settlement activity in September 2025; Ahava’s CEO Ron Michael disputes the listing, stating manufacturing has moved into “undisputed Israeli territory” and that the Mitzpe Shalem site is owned by a local kibbutz, and that Ahava is “working to correct” the UN listing ⁷. Critically, Boots is not named anywhere in this article; the piece states Ahava remains available through unnamed “other UK and international online retailers,” without identifying any of them ⁷. A direct attempt to independently verify the September 2025 Ahava/Fosun UN-database addition against the underlying OHCHR press release failed with an HTTP 403 error, so this claim currently rests on the Jewish News secondary report only ⁸. This finding is offered as updated sector/comparator context relevant to the audit’s unresolved, pre-2020 Boots–Ahava supplier lead; it does not itself establish any current Boots–Ahava relationship, and no public evidence identified of Boots selling, listing, or being alerted about Ahava products in 2025–2026. Updated-shard searches of 2026 advocacy/trade reporting on Israeli agricultural exporters Mehadrin, Hadiklaim, and D. Hai Marketing’s date and citrus exports named Costco, Loblaws (“Carrefour” brand per one snippet), and Chinese trade-fair buyers (Shanghai/Guangzhou, June 2026) as purchasers, but no public evidence identified naming Boots in any of this reporting ^{9, 10, 11, 12}.

Product Origin, Labeling & Regulatory Compliance

No public evidence identified of Boots selling settlement-labeled or “Produce of Israel” mislabeled goods; general UK coverage of a 2026 West Bank import ban was retrieved but contains no Boots-specific reference ¹³. The 2008 Jewish Chronicle reporting on the Ahava supply relationship did not address product labeling or country-of-origin disclosure practices for the cosmetics in question ¹. The unresolved New Pharm franchise discussions described below similarly carry no identified regulatory or labeling documentation ^{1, 2}. The 2026 Jewish News reporting on the UN database’s Ahava/Fosun addition and the Mitzpe Shalem settlement-site photographs likewise contains no Boots-specific labeling or regulatory content ⁷. No further labeling- or regulatory-compliance findings were surfaced in the updated research shards; this sub-category remains otherwise unchanged.

Investment, Capital & Financial Exposure

Boots UK Limited’s ultimate former parent, Walgreens Boots Alliance, Inc. (WBA), was taken private by US private-equity firm Sycamore Partners in a transaction reported in trade press at up to $23.7 billion, with WBA shareholders approving the sale on 11 July 2025 and the deal closing 28 August 2025 ^{14, 15, 16}. This $23.7 billion figure is now directly confirmed by a primary SEC filing: WBA’s own Form 8-K, Exhibit 99.1 press release (filed/dated on or around 6 March 2025, announcing the merger agreement) states verbatim, “The total value of the transaction represents up to $23.7 billion,” with a footnote defining this as cash consideration of $11.45 per share plus up to $3.00 per share under a contingent “DAP Right” (tied to future monetization of VillageMD-related assets), plus net debt, capital leases, the present value of opioid liability and the Everly settlement, less the fair value of certain equity investments ¹⁷. The release separately defines “Total Consideration” - the pure per-share cash payout of $11.45 plus up to $3.00 contingent DAP Right - as distinct from the broader $23.7bn enterprise-level figure ¹⁷. A later, separately sourced trade-press article (Insurance Journal, 8 October 2026) describes the same 2025 Sycamore/WBA take-private as a “$10 billion” deal; this figure is not corroborated by any primary SEC filing located in this research, including the WBA merger-agreement press release ¹⁷ and the deal-closing 8-K ¹⁶. An unverified reconciliation hypothesis - not established from any primary source and flagged as inference only - is that $11.45/share cash consideration multiplied by WBA’s then-outstanding share count (publicly reported at the time as roughly 862–869 million shares) arithmetically approximates $9.9–10.0 billion, suggesting the “$10 billion” figure circulating in some press (Insurance Journal, and a Private Equity Wire headline using the same figure) may describe only the base per-share cash/equity purchase price, while “$23.7 billion” is the broader enterprise-value figure inclusive of assumed debt and other liabilities ^{18, 19}. This resolves, in favor of $23.7 billion as WBA’s own primary-sourced “total value of the transaction,” the discrepancy the prior audit draft had flagged as unresolved ^{18, 17}.

Per WBA’s own SEC filing, Stefano Pessina and his family “reinvested 100% of their interests” in the business as part of the Sycamore transaction, retaining an ownership stake in the group that now controls Boots ²⁰. The Boots Group’s own 26 January 2026 statement confirms Sycamore Partners, “working with Stefano Pessina and his family,” acquired WBA and then separated The Boots Group - alongside Boots (UK), Alliance Healthcare Germany, and Farmacias Benavides - into an autonomously operating entity reporting to The Boots Group Board ²¹. Secondary trade press (not independently verified against a primary corporate or stock-exchange announcement) reports incoming CEO Alex Baldock’s appointment occurred ahead of a possible London IPO valued at £5–7 billion ^{22, 23}. No IRS Form 990 or 990-PF filing for any foundation bearing Stefano Pessina’s name was located via ProPublica Nonprofit Explorer, meaning no grant schedule exists to review for Israel/Palestine-linked recipients under that name in the US jurisdiction searched ²⁴. WBA’s FY2023 SEC Exhibit 21 significant-subsidiary list (30 entities) names no subsidiary located in or named for Israel, with jurisdictions limited to the US, England & Wales, Ireland, Jersey, Luxembourg, Mexico, and the Netherlands, though the exhibit discloses that non-”significant” subsidiaries are omitted and so cannot rule out a smaller Israeli entity ²⁵. A direct UK Charity Commission name-search for “Pessina” returned HTTP 403 and could not be retrieved, and a Companies House-and-general-web-search check similarly located no principal-linked charitable vehicle; combined with the prior ProPublica result, no principal-linked foundation has yet been located in either the US or UK jurisdictions searched, though this is a source-scoped absence covering only two jurisdictions, not a confirmed absence across all possible registers ²⁶.

A second, later ownership change was announced on 7 October 2026: Fairfax Financial Holdings Limited’s own Form 6-K, Exhibit 99.1 filing confirms Fairfax is partnering with Wittington Investments, Limited (the Weston family’s Canadian private holding company) to acquire The Boots Group for a purchase price of approximately US$8.9 billion, inclusive of assumed debt ²⁷. Fairfax’s equity commitment is up to approximately US$2.3 billion under an equity commitment letter, with Fairfax expected to hold 50% of Boots’ equity post-closing and Wittington retaining operational control; Galen Weston is expected to serve as Chair of Boots post-closing ^{27, 28}. The acquired business perimeter per the same filing is Boots retail operations in the UK and Ireland, Boots Opticians, the No7 Beauty Company, and Boots’ Thailand and franchised businesses, with Farmacias Benavides and Alliance Healthcare Deutschland explicitly excluded and “retained by their current owner” ^{27, 18}. Expected completion is Q1 2027, subject to customary closing conditions and “certain regulatory approvals,” with no specific regulator or jurisdiction named in either primary source retrieved ^{27, 29}. Skadden’s own deal-announcement page (Skadden acted as Wittington’s legal advisor) independently names Sycamore Partners and the Pessina family as the sellers, the first primary-source confirmation in this audit naming Sycamore and the Pessina family explicitly as counterparty-sellers in this transaction, and is consistent with the prior Sycamore/Pessina ownership findings above ²⁹. Secondary trade press (search-snippet corroboration only, not independently fetched) is consistent on deal value, partners, and expected close, and one outlet is the apparent source for the 50% Fairfax equity figure that the Fairfax filing itself also states directly ^{30, 31, 18, 32, 33}. Insurance Journal additionally reports, uncorroborated by the primary filings, that Boots has “over 1,800 stores and more than 50,000 employees” and that Wittington “plans to upgrade stores, optimize the online experience, and expand healthcare services” ¹⁸. This Fairfax/Wittington transaction supersedes and extends, but does not contradict, the audit’s prior Sycamore take-private findings; it is a second, later, pending ownership change layered on top of the Sycamore/Pessina-controlled Boots Group structure.

A separately dated transaction - the 24 November 2023 full buy-in of the Boots Pension Scheme with Legal & General - is also recorded here. Boots UK’s own newsroom release confirms a £4.8 billion (reported as $6.0 billion) full buy-in, covering all approximately 53,000 members (retirees and deferred members combined, with no further breakdown given), then described as the largest single transaction of its kind ²⁸. Per the release, “most of the Scheme’s economic risk” - market movements, longevity/life-expectancy risk, and other uncertainties - transfers to Legal & General, and the Scheme’s assets transfer in an orderly way; members subsequently receive individual annuity policies directly from L&G, which pays benefits directly going forward, enabling the Scheme to be wound up over up to two years from the announcement ²⁸. Boots/WBA brought forward approximately £170m ($210m) of already-committed scheme payments and committed approximately £500m ($630m) of additional contributions, with a deferred premium facility with L&G providing flexibility on settlement timing ²⁸. A prior WBA group-level guarantee to the Scheme was terminated and replaced with a smaller, tapering temporary guarantee - a direct, primary-sourced confirmation that WBA’s financial backstop to the UK pension scheme was wound down as part of this transaction ²⁸. Named quotes on record: Alan Baker (Law Debenture, Chair of the Pension Scheme Trustee) states the deal “remov[es] market uncertainty and other financial exposures” and that the Scheme is no longer reliant on Boots to pay members directly; Sebastian James (then Managing Director, Boots UK & Ireland) calls it “the gold standard outcome for our pension scheme”; Andrew Kail (CEO, L&G Retirement Institutional) describes it as L&G’s largest-ever single transaction ^{28, 34}. Pensions Age trade-press coverage corroborates these figures and quotes and adds a quote from John Baines (Aon) on “the significant portfolio of illiquid investments held by the scheme,” but gives no completion/wind-up date beyond the “up to two years” estimate, and no subsequent modification, dispute, or status change to the buy-in since 24 November 2023 was located in this research ³⁴. Corroborating but not independently fetched secondary sources on this transaction include Legal & General’s own newsroom release, RTÉ, Bloomberg Law, and a Legal & General RNS filing PDF (“Project Bowline”) ^{35, 36, 37, 38}. The L&G pension buy-in is confirmed to predate both the 2025 Sycamore/Pessina take-private and the pending October 2026 Fairfax/Wittington acquisition, and no evidence was located that the pension arrangement has been altered, revisited, or made contingent on either subsequent ownership change.

Operational Presence & Market Activity

Boots UK Limited (company no. 00928555) is a private limited company incorporated 11 March 1968, registered in Nottingham, with SIC codes covering non-specialised retail and dispensing-chemist activities ³⁹. A 2008 Jewish Chronicle report described Boots in discussions to enter the Israeli market by rebranding New Pharm - then Israel’s second-largest pharmacy chain, with 56 stores plus 30 concessions in Hamashbir Lazarchan department stores and 2007 sales of £131m - as “Boots Israel” on a franchise basis ¹. No source confirms this franchise rebranding was ever consummated; the Jewish Chronicle article describes it only as reported negotiation, and no public evidence identified of its outcome ¹. A BDS Movement campaign page frames Boots as a prospective “primary target” of a boycott campaign in connection with the 2008 Israel-entry reports, though this is advocacy framing drawn from the same underlying 2008 reporting rather than independent confirmation ². WBA’s corporate “International Segment” page, which per prior search snippets names Middle East franchise-partner countries (UAE, Saudi Arabia, Bahrain, Oman, Kuwait, Qatar, plus Indonesia) without listing Israel, could not be fetched (HTTP 404) and remains unverified ⁴⁰.

Subsequent research attempted to resolve Boots’ current international/franchise footprint directly from Boots Middle East and Alshaya operator pages. Two primary-page fetch attempts failed outright: the Alshaya Group corporate “About us”/timeline page returned a TLS certificate verification error ⁴¹, and a Zawya press release on a Boots Terminal 3 Dubai Airport store opening returned HTTP 400 ⁴²; a separate attempt to fetch Boots Saudi Arabia’s own “About Us” page (sa.boots.com) returned only the literal string “Metadata,” with no substantive content extracted ⁴³, and a fetch of an Arabian Business article on the Alshaya/Boots Gulf entry returned HTTP 403 ⁴⁴. A further attempt in the updated research to retrieve the Alshaya timeline via a web.archive.org mirror also failed, as the fetch tool used does not support archive.org retrieval, so this gap remains unresolved ⁴¹. As a result, the specific figures cited in some search-engine snippets and in the examiner’s question - including a claim that Alshaya operates 111 Boots stores across Saudi Arabia, UAE, Kuwait, Qatar, and Bahrain, and a claim of a Boots UAE store reopening in October 2026 - could not be confirmed or disconfirmed from any retrieved primary source; no public evidence identified verifying either the 111-store figure or the October 2026 UAE reopening claim specifically, and a dedicated search for the reopening claim returned no relevant results. Unfetched search-snippet evidence (flagged as such, not established fact) indicates Boots entered the Gulf under a master franchise agreement with M.H. Alshaya Co. (Alshaya Group), with the first stores opening in Kuwait and Dubai around 2005–2006 and subsequent expansion to Bahrain and Qatar ^{45, 46, 47}; one unfetched snippet references a Dubai Airport Terminal 3 store described as the “61st store in the region,” and other unfetched snippets reference Alshaya operating “90 Boots stores” (undated) and “7 Dubai locations and 20 across the region” (undated) - none of these figures were independently verified against a live, dated primary page. Current (as of the October 2026 research date) Alshaya internal careers-portal job postings for Boots-branded roles were independently identified in UAE (Online Merchandiser, Senior Buyer), Kuwait (Buyer), Bahrain (Pharmacist), and Saudi Arabia (Area Manager), indicating an ongoing, active Alshaya-operated Boots retail presence in those four markets as of the research date; job postings are not a corporate store-count disclosure, and Qatar was not independently confirmed in any source retrieved in this research ^{48, 49, 50, 51, 52}.

On Thailand, unfetched search-snippet evidence describes Boots Retail (Thailand) Limited as a locally incorporated company (incorporated 1996 per one company-profile snippet) with historically company-owned, not franchised, stores, with store-count snippets varying by year and not reconciled (approximately 200 stores in 2012; 277 stores in 2017; a later undated snippet citing 240 stores) ^{53, 54, 55, 56}. This creates a direct, unresolved tension with the Fairfax SEC exhibit’s own language, which groups “Boots’ Thailand and franchised businesses” together in a single acquired-perimeter clause ²⁷ - the exhibit’s phrasing is ambiguous as to whether it treats the Thailand business itself as franchised or bundles it with a separately franchised business line in the same clause, and this ambiguity should be flagged rather than resolved by inference. The Fairfax/Wittington filing’s explicit inclusion of “Thailand and franchised businesses” in the acquired perimeter does, at the ownership-structure level, corroborate that Alshaya’s (and any other) Boots franchise operations are bound up in the pending sale, though neither primary document (Fairfax’s SEC exhibit or Skadden’s announcement) names Alshaya, the Gulf states, or any specific franchise partner ^{27, 29}.

Corporate Structure & Foundational Ties

Boots UK Limited’s previous registered name was Boots The Chemists Limited, changed to Boots UK Limited on 1 October 2007 ³⁹. Boots UK Limited’s official Companies House persons-with-significant-control (PSC) register lists exactly one PSC entry: Alliance Boots Holdings Limited (company no. 04452715, England & Wales), notified 6 April 2016, with nature of control recorded as ownership of 75% or more of both shares and voting rights ⁵⁷. The prior draft of this audit stated that “WBA Acquisitions UK Holdco 7 Limited” - the entity named only in a third-party menna.ai mirror in prior research - does not appear anywhere on the official PSC register ^{58, 59, 57}; updated research corrects and refines this by direct primary-source fetch of a different, upstream register. A direct WebFetch of the official Companies House PSC register for Alliance Boots Holdings Limited itself (company no. 04452715) - not previously checked at that specific tier - shows exactly one active PSC: “Wba Acquisitions Uk Holdco 7 Limited” (registration number 08155146, registered office Sedley Place, 361 Oxford Street, London W1C 2JL), status active, notified 6 April 2016, with nature of control recorded as ownership of 75%+ of shares, 75%+ of voting rights, and the right to appoint or remove directors, and no cessation date shown as of the 30 October 2026 research date ⁶⁰. The two findings are not contradictory: they describe different companies at different tiers of the same ownership chain. Boots UK Limited’s own PSC register correctly names only Alliance Boots Holdings Limited ⁵⁷; one tier further up, Alliance Boots Holdings Limited’s own PSC register names Wba Acquisitions Uk Holdco 7 Limited as its active controlling entity ⁶⁰. The confirmed structural reading is therefore: Boots UK Limited → (PSC) Alliance Boots Holdings Limited (04452715) → (PSC) Wba Acquisitions Uk Holdco 7 Limited (08155146). The menna.ai-sourced lead is accordingly corroborated, not refuted, once the correct tier of the register is consulted; the entity is real and is an active, currently-controlling PSC of record one level above Alliance Boots Holdings Limited. The exact mechanism or identity of Wba Acquisitions Uk Holdco 7 Limited’s own parent/PSC, and whether its 2016-dated PSC filing has itself been updated to reflect the 2025 Sycamore take-private or the pending 2026 Fairfax/Wittington transaction, was not checked in this research and remains an open lead ⁶⁰. The Boots Group Intermediate Limited (company no. 16480067), incorporated 28 May 2025 in Altrincham, Cheshire, with SIC code 64209 (holding company activities), was originally registered under the name “Blazing Star Boots Intermediate Limited” before being renamed on 9 July 2025 - a transaction-naming pattern consistent with a holding vehicle created around the mid-2025 WBA/Sycamore transaction ⁶¹.

Stefano Pessina is named by the company as a controlling principal alongside Sycamore Partners in the WBA acquisition and remains a Director of The Boots Group Board as of 9 February 2026 after stepping down as Chairperson ²¹. Ornella Barra, WBA Co-Chief Operating Officer from 2016 and The Boots Group CEO from August 2025, became Chairperson of The Boots Group Board effective 9 February 2026, succeeding Pessina, and the company states she “remains a shareholder and board member of the standalone companies that were formerly part of” WBA ²¹. Boots UK Limited’s official Companies House officers register shows 55 officers total (51 resigned, 4 active); the four active officers as of the research date are: Andrew Richard Thompson (Secretary, since 2 October 2015), Alexander David Baldock (Director, since 1 September 2026, formerly CEO of Currys plc), Samuel James Hunter (Director, since 22 May 2023), and Jamie Kerruish (Director, since 17 September 2024) ^{62, 63, 64}. No officer on this register carries a “Chair” title; the Chair role (Ornella Barra) sits at The Boots Group Board level, not at the Boots UK Limited subsidiary level ⁶⁴. Recent former directors include Anthony Hemmerdinger (2 February 2024–31 August 2026) and Sebastian James (3 October 2018–2 November 2024) ^{62, 65}.

Samuel James Hunter holds (or has held) 25 director appointments across Boots-affiliated group entities per Companies House, including Boots UK Limited, Boots Management Services Limited, Boots Hearingcare Limited, The Boots Company PLC, Boots Properties Limited, Boots Digital Health Limited, and Conceptra Diagnostics Limited, most dated 22 May 2023, with two opticians-related appointments resigned 19 April 2024 and several historic group entities shown as dissolved ⁶⁶. A name-specific web search for Jamie Kerruish’s biography, political contributions, lobbying activity, board affiliations, or Israel/Palestine nexus returned no relevant results beyond the Companies House appointment record, a source-scoped absence rather than a confirmed absence across dedicated political-donation or lobbying registers ⁶⁴. A parallel name-specific search for Samuel James Hunter similarly returned no press biography or political/lobbying/foundation record beyond the Companies House appointment data, also a source-scoped (Companies House plus general web search) absence ⁶⁶. A direct attempt to query the UK Electoral Commission’s donations-search tool for “Baldock” did not execute a processed query and returned only the tool’s default unfilled state, so the previously reported 2015 Guardian-sourced Conservative Party donor claim for Alex Baldock remains unverified against the Commission’s primary donor register ^{63, 67}.

John Lederer was appointed Executive Chairman of Walgreens at the Sycamore deal’s close as a former WBA director and Senior Advisor to Sycamore Partners, and Mike Motz was appointed Walgreens CEO, previously CEO of Staples U.S. Retail (a Sycamore portfolio company) ²⁰. A search-snippet characterization (not independently fetched) of WBA’s 28 August 2025 deal-completion 8-K additionally names Stefano Pessina, Stefan Kaluzny, and Kevin Burke as directors effective on completion, alongside Mike Motz as CEO; this corroborates, but does not independently re-verify, the audit’s prior completion-date and personnel findings ⁶⁸. Stefan Kaluzny, co-founder of Sycamore Partners and a controlling-principal-adjacent figure in the 2025 WBA take-private, was searched by name; a secondary aggregator (LittleSis, dev-subdomain) reportedly lists Kaluzny-linked political contributions to the US Democratic National Committee (approximately $54,900), Chuck Schumer (joint/co-donor), Barack Obama, Tim Scott, Mitt Romney, and Rod Blagojevich, with no Israel-linked recipient, pro-Israel PAC, AIPAC, or Israeli-candidate donation identified in the snippet ⁶⁹. This claim rests solely on a WebSearch snippet summary; a direct WebFetch of the LittleSis page itself was blocked by bot-protection, and no FEC.gov or OpenSecrets.org primary-source cross-check was completed, so per the audit’s aggregator-sourcing rule this is flagged as snippet-only and unverified, not established fact ⁶⁹.

Turning to the newly identified 7 October 2026 transaction: the buyer is Wittington Investments, Limited, the Weston family’s private holding company, with Galen Weston expected to serve as Chair of Boots post-closing ^{27, 29}. Fairfax Financial Holdings Limited is the co-investing partner, committing up to approximately US$2.3 billion for an expected 50% equity stake ²⁷. Neither the Fairfax SEC exhibit nor Skadden’s announcement page discloses any Israel-nexus detail for Fairfax, Wittington, or Galen Weston, and no dedicated named-entity search on these newly surfaced principals (Fairfax Financial, Wittington Investments, Galen Weston, Alshaya Group/M.H. Alshaya Co., Legal & General, Alan Baker, Andrew Kail) was completed within the research budget; these remain open leads rather than confirmed-absence findings.

Profit Repatriation & Economic Contribution

A secondary aggregator snippet (not independently fetched from the Senate Lobbying Disclosure Act database) reported $50,000 of “WALGREENS CO.” lobbying disclosed for Q3 2025, covering pharmacies, pharmacists, Medicare reimbursement, opioids, vaccines, and Pharmacy Benefit Managers, with no Israel/Palestine-related lobbying subject identified in the disclosure summary ⁷⁰. This is a company-level, US-focused lobbying record not specific to Boots UK, and should be treated as an unverified lead requiring direct Senate LDA database confirmation. No public evidence identified of any Boots UK-specific profit-repatriation arrangement, tax ruling, or economic-contribution disclosure tied to Israel or Israeli-administered territories; this finding stands unchanged after the updated research, and no Israel-nexus content was found or searched in connection with the newly identified Fairfax/Wittington transaction, the L&G pension buy-in, or the Alshaya Middle East franchise footprint within the completed research shards - these remain open leads for a dedicated economic-contribution shard rather than confirmed findings in either direction.